Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIVIA: W_ova1 Vaccine in Ovarian Cancer
NCT04163094Phase 1Terminated
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2019
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of W-OVA1 in ovarian cancer, sponsored by University Medical Center Groningen. Primary endpoint: Change from baseline W_ova1 vaccine antigen-specific T cells in the peripheral blood. Started Nov 2019; status: terminated.
02
Drugs
W-OVA1
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04163094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163094.